文献速递消化系统肿瘤

消融放疗与不可手术胰腺癌患者生存的关联

Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项队列研究纳入119例局部进展期胰腺癌患者,接受98 Gy生物有效剂量的消融放疗,中位总生存期自诊断起为26.8个月,自放疗起为18.4个月,12个月和24个月总生存率分别为74%和38%,局部区域失败累积发生率分别为17.6%和32.8%,3级上消化道出血发生率为8%,无4-5级事件。

要点

  • 消融放疗联合诱导化疗与持久的局部区域控制和较好的生存相关
  • 自放疗起中位总生存期18.4个月,24个月生存率38%
  • 3级上消化道出血发生率8%,无4-5级毒性

核心结论

  • 对于不可手术的局部进展期胰腺癌,多药诱导化疗后行消融放疗与持久的局部区域肿瘤控制和较好的生存相关。
  • 有必要在局部进展期胰腺癌患者中开展前瞻性随机试验。

研究设计与样本

  • 这项队列研究纳入2016年6月至2019年2月间连续接受消融放疗的119例患者,并录入前瞻性维护的数据库。
  • 患者均在接受标准化技术治疗,来自大型学术癌症中心区域网络。
  • 纳入标准为局部、不可切除或医学上不可手术的胰腺癌,肿瘤任何大小且与主肿瘤管腔接触小于5 cm。

主要发现

  • 119例患者中59例男性,中位年龄67岁;99例为T3/T4期,53例淋巴结阳性,中位CA19-9水平大于167 U/mL。
  • 116例(97.5%)接受了诱导化疗,中位持续4个月(范围0.5-18.4个月)。
  • 自诊断和自消融放疗起的中位总生存期分别为26.8个月和18.4个月。
  • 自消融放疗起12个月和24个月总生存率分别为74%(95% CI,66%-83%)和38%(95% CI,27%-52%)。
  • 12个月和24个月局部区域失败累积发生率分别为17.6%(95% CI,10.4%-24.9%)和32.8%(95% CI,21.6%-44.1%)。

关键数值与推荐

  • 消融放疗采用98 Gy生物有效剂量,使用标准设备,并应用呼吸门控、软组织图像引导和选择性自适应计划来应对器官运动并限制周围管腔器官剂量。

临床怎么用

  • 对于不可手术的局部进展期胰腺癌患者,可考虑在多药诱导化疗后采用消融放疗以达到持久的局部区域控制和较好的生存。
  • 治疗时应使用呼吸门控、软组织图像引导和选择性自适应计划等技术来限制周围管腔器官的剂量。

局限性

  • 本研究为队列研究,非随机对照试验,可能存在选择偏倚和混杂因素。
  • 样本量有限,且来自单一学术癌症中心区域网络,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Surgical resection has been considered the only curative option for patients with pancreatic cancer. Nonoperative local treatment options that can provide a similar benefit are needed. Emerging radiation techniques that address organ motion have enabled curative radiation doses to be given in patients with inoperable disease. OBJECTIVE: To determine the association of hypofractionated ablative radiation therapy (A-RT) with survival for patients with locally advanced pancreatic cancer (LAPC) treated with a novel radiation planning and delivery technique. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 119 consecutive patients treated with A-RT between June 2016 and February 2019 and enrolled in a prospectively maintained database. Patients were treated with a standardized technique within a large academic cancer center regional network. All patients with localized, unresectable, or medically inoperable pancreatic cancer with tumors of any size and less than 5 cm luminal abutment with the primary tumor were eligible. INTERVENTIONS: Ablative RT (98 Gy biologically effective dose) was delivered using standard equipment. Respiratory gating, soft tissue image guidance, and selective adaptive planning were used to address organ motion and limit the dose to surrounding luminal organs. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). Secondary outcomes included incidence of local progression and progression-free survival. RESULTS: Between 2016 and 2019, 119 patients (59 men, median age 67 years) received A-RT, including 99 with T3/T4 and 53 with node-positive disease, with a median carbohydrate antigen 19-9 (CA19-9) level greater than 167 U/mL. Most (116 [97.5%]) received induction chemotherapy for a median of 4 months (0.5-18.4). Median OS from diagnosis and A-RT were 26.8 and 18.4 months, respectively. Respective 12- and 24-month OS from A-RT were 74% (95% CI, 66%-83%) and 38% (95% CI, 27%-52%). Twelve- and 24-month cumulative incidence of locoregional failure were 17.6% (95% CI, 10.4%-24.9%) and 32.8% (95% CI, 21.6%-44.1%), respectively. Postinduction CA19-9 decline was associated with improved locoregional control and survival. Grade 3 upper gastrointestinal bleeding occurred in 10 patients (8%) with no grade 4 to 5 events. CONCLUSIONS AND RELEVANCE: This cohort study of patients with inoperable LAPC found that A-RT following multiagent induction therapy for LAPC was associated with durable locoregional tumor control and favorable survival. Prospective randomized trials in patients with LAPC are warranted.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Reyngold M, O'Reilly EM, Varghese AM, et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol. 2021. PMID: 33704353. doi:10.1001/jamaoncol.2021.0057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。